EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Neratinib and the Role of Anti‐ HER2 Therapy in Salivary Duct Carcinoma

Martina Napolitano, Lucia Trudu, Enrica Martinelli iD, Chiara Santini, Massimo Dominici, Federica Bertolini

Cancer Reports · 2025

DOI: 10.1002/cnr2.70065 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Martina Napolitano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Quinolines, Salivary Gland Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgroud Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over‐expression. Case We report the case of a 64‐year‐old female with extra‐ and intracranial metastases of SDC with evidence of AR and HER2 overexpression. After progression on first line chemotherapy, was administered neratinib, a pan‐Erb2 receptor tyrosine kinase inhibitor. Even with central nervous system involvement at diagnosis, a durable clinical response was obtained with a PFS of 11 months and no significant toxicities to manage. Best response observed during tratment was partial response. Conclusions This case confirms the potential efficacy of neratinib in HER2‐positive SDC and underlines the need to define the best therapeutic sequence and potential biomarkers for these rare patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesQuinolinesSalivary Gland NeoplasmsProtein Kinase InhibitorsHumansFemaleMiddle AgedSalivary DuctsReceptors, Androgen

Stichwörter der Autor:innen

HER2 targeted therapyhead and neckneratinibprecision medicinesalivary duct carcinoma

Substanzen

Erb-b2 Receptor Tyrosine KinasesQuinolinesProtein Kinase InhibitorsReceptors, AndrogenneratinibERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • PhD Program Clinical and Experimental Medicine, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • AULSS7 Pedemontana-Unità Operativa Complessa di Oncologia, Italy.

ORCID-Profile: Enrica Martinelli

Zitieren

APA

Napolitano, M., Trudu, L., Martinelli, E., Santini, C., Dominici, M., & Bertolini, F. (2025). Neratinib and the Role of Anti‐ HER2 Therapy in Salivary Duct Carcinoma. Cancer Reports. https://doi.org/10.1002/cnr2.70065

Vancouver

Napolitano M, Trudu L, Martinelli E, Santini C, Dominici M, Bertolini F. Neratinib and the Role of Anti‐ HER2 Therapy in Salivary Duct Carcinoma. Cancer Reports. 2025. doi:10.1002/cnr2.70065

BibTeX
@article{Napolitano2025,
  author = {Napolitano, Martina and Trudu, Lucia and Martinelli, Enrica and Santini, Chiara and Dominici, Massimo and Bertolini, Federica},
  title = {Neratinib and the Role of Anti‐ HER2 Therapy in Salivary Duct Carcinoma},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70065}
}
Kostenlos starten →